title: Association of anti-Ro/SSA antibody with response to biologics in patients with rheumatoid arthritis.
abstract: OBJECTIVE
  To compare the effectiveness of three different biologics in anti-Ro/SSA antibody-positive and antibody-negative patients with rheumatoid arthritis (RA).
  
  
  METHODS
  The study subjects were 110 biologics naïve patients with RA who started treatment with biologics and examined for anti-Ro/SSA antibody between December 2003 and March 2014. For patients treated with intravenous infliximab (IFX), tocilizumab (TCZ), or abatacept (ABT), we compared the clinical characteristics and changes in composite disease activity index, such as DAS28, SDAI, and CDAI, for 12 months in anti-Ro/SSA antibody-positive and antibody-negative patients.
  
  
  RESULTS
  We examined 59 patients (nine were positive and 50 were negative for anti-Ro/SSA antibody) treated with IFX, 27 patients (5 positive and 22 negative) treated with TCZ, and 24 patients (13 positive and 11 negative) treated with ABT. For patients treated with IFX, parameters of disease activity did not change significantly from baseline in anti-Ro/SSA antibody-positive patients, whereas they improved in antibody-negative patients. On the other hand, treatment with TCZ and ABT significantly decreased disease activity, relative to baseline, in both anti-Ro/SSA antibody-positive and antibody-negative patients. Anti-Ro/SSA antibody-positive patients treated with IFX showed higher frequency of HACA and seroconversion of ANA, and lower serum TGF-β levels.
  
  
  CONCLUSIONS
  Positivity to anti-Ro/SSA in RA seems to confer resistance to IFX via production of HACA and ANA, and low serum TGF-β levels, but not to TCZ and ABT.
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Shinya
authors.initials: S
authors.lastname: Hagiwara
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Hiroto
authors.initials: H
authors.lastname: Tsuboi
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Fumika
authors.initials: F
authors.lastname: Honda
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Hidenori
authors.initials: H
authors.lastname: Takahashi
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Izumi
authors.initials: I
authors.lastname: Kurata
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Ayako
authors.initials: A
authors.lastname: Ohyama
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Mizuki
authors.initials: M
authors.lastname: Yagishita
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Saori
authors.initials: S
authors.lastname: Abe
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kurashima
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Syunta
authors.initials: S
authors.lastname: Kaneko
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Hoshimi
authors.initials: H
authors.lastname: Kawaguchi
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takahashi
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ebe
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yokosawa
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Asashima
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Tomoya
authors.initials: T
authors.lastname: Hirota
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Naoto
authors.initials: N
authors.lastname: Umeda
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Yuya
authors.initials: Y
authors.lastname: Kondo
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Isao
authors.initials: I
authors.lastname: Matsumoto
authors.affiliation: a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Sumida
mesh_terms: D000069594:Abatacept / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000097:blood*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology*; D001688:Biological Products / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000974:Antibodies, Antinuclear; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D001688:Biological Products; C035356:SS-A antibodies; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D000069594:Abatacept; D000069285:Infliximab; C502936:tocilizumab
keywords: Abatacept (ABT)rheumatoid arthritis; Anti-Ro/SSA antibody; Infliximab (IFX); Tocilizumab (TCZ)